Which two US NSCLC brands are streets ahead of the competition?
There are various options available to US medical oncologists to treat non-small cell lung cancer (NSCLC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?
NPS+ NSCLC (US) gives a unique insight into the overall brand health of 12 leading treatments for NSCLC currently being used in the US. 100 medical oncologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
Two brands are streets ahead of the competition. And one of these brands has hardly any detractors. Which one is it, and why is it trouncing the competition?
Loyalty for the leading brand bucks the trend. Loyalty scores of 4 or more are what brands are aiming for, and the leading brand is clearly doing something right. But why is loyalty so low at the other end of the league table?
High levels of satisfaction, but at what cost? Medical oncologists in the US seem to be a satisfied bunch, but is that due to one particular treatment option, or because they have a wide range of choices? And what could improve satisfaction rates even further?
Winning over detractors could drive significant market share growth for some brands.But which ones? Old, established therapies or the new kids on the block?
Marketing messages for some brands will be key. Are any brands associated with key product attributes such as slowing progression, good efficacy and a positive risk/benefit profile? If not, what could be done to drive better brand association?
In their own words. What do doctors say each brand means to them? For example, which brand is described as the ‘new, easy to use, but very expensive’ and which brand ‘has no role in the treatment of NSCLC’?
We surveyed 100 US medical oncologists chosen from the largest community of validated physicians in the world.
We conducted the survey between 3rd and 13th July 2017.
Explore Important Brand Loyalty Issues
NPS+ NSCLC (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing small molecule and biologic treatments to patients with NSCLC. You’ll discover:
How satisfied doctors are with available treatments. How loyal doctors are to your brand. How many other brands your Promoters recommend. Which other brands your Promoters and Detractors recommend. How much market share your brand has among Promoters and Detractors. How much market share you stand to gain by converting Detractors into Promoters. Which messages Promoters, Passives and Detractors associate with your brand. Your brand DNA: what doctors really think of your brand—in their own words.
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question: "How likely are you to recommend this brand to a colleague?" Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:
Detractors are those who answer 0 – 6. Passives are those who answer 7 – 8. Promoters are those who answer 9 - 10.
How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
Our reports have been used by over 10K customers, including:
Pancreatic Cancer Therapeutics Market Research Report by Product (Chemotherapy and Targeted Therapy), by Type (Endocrine Pancreatic Cancer and Exocrine Pancreatic cancer) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Pancreatic Cancer Therapeutics Market is expected to grow from USD 2,281.65 Million...
Breast Cancer Liquid Biopsy Market Research Report by Biomarker (Cell-free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), and Other Circulating Biomarkers), by End-User (Hospitals & Physician Laboratories and Reference Laboratories) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The...
‘Non-muscle Invasive Bladder Cancer (NMIBC)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted NMIBC epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Non-muscle Invasive Bladder Cancer (NMIBC) Understanding Non-muscle...
Cervical Cancer Drugs Market Research Report by Indication (Advanced Invasive Stage, Early Invasive Stage, and Pre-malignant Lesions), by Treatment Type (Chemotherapy, Cold Knife Cone Biopsy, Cone Biopsy, Cryotherapy, and Hormone Therapy), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global...
Serine/Threonine Protein Kinase Pim 3 - Pipeline Review, H2 2020 Summary Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 22.214.171.124) - Serine/threonine-protein kinase Pim-3 is an enzyme encoded by the PIM3. It prevents apoptosis. It contribute to tumorigenesis through the delivery...
2024 Italy Hospital Tumor Marker Testing Market: Supplier Shares by Test and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentstion Review, Emerging Opportunities This new report contains 525 pages and 38 tables.The report is available by section, and can be customized to specific information...
Carcinoembryonic Antigen Market Value forecast, New Business Opportunities and Companies: Outlook By Type, Application, By End User and By Country, 2020- 2026 The study predicts the short term and long term trends that can shape up the future of the Carcinoembryonic Antigen market including the COVID-19 pandemic implications...
Global Next-Generation Breast Cancer Diagnostics and Screening Market to Reach $10.48 Billion by 2030 Market Report Coverage - Next Generation Breast Cancer Diagnostic and Screening Market Segmentation • Product Type - BRCA tests, ER/PR tests, HER2 tests • Technology- Real-Time Polymerase...
The growing prevalence of several types of cancers in cats and dogs, as well as an increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. According to the Veterinary Cancer Society, cancer was the leading cause of death in 47% of dogs, especially those that are over the age of 10, and...
‘High-grade Glioma (HGG) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted High-grade Glioma (HGG) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. High-grade Glioma (HGG) Understanding Highly malignant...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.